Ketorolac Accord (Ketorolac Trometamol)

Ketorolac Trometamol works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which prevents the formation of prostaglandins. Reduced prostaglandin levels lead to decreased inflammation, lower pain signalling, and less sensitisation of nerve endings.

The exact dose and dosing schedule of Ketorolac Accord are determined by the prescribing clinician based on the patient’s condition, age, renal function and other factors. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Safety data for Ketorolac Trometamol in pregnancy and lactation are limited. It is generally avoided during the third trimester because of potential fetal renal effects, and caution is advised while breastfeeding. Clinicians should weigh the benefits against potential risks before prescribing.

To request Ketorolac Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ketorolac is distinguished by its potent analgesic effect, often comparable to weak opioids, making it useful for short‑term severe pain. Unlike many NSAIDs, it is typically limited to a five‑day course because of higher risks of gastrointestinal and renal adverse events.

Ketorolac Accord should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Ketorolac Accord is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed. It is recommended to take the medication with food or an antacid to lessen gastrointestinal irritation.

The most serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, cardiovascular events such as myocardial infarction, and life‑threatening allergic reactions. Patients should be monitored closely for signs of these complications, especially when used with other high‑risk drugs.

Ketorolac Accord should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, those with active peptic ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, and in the third trimester of pregnancy. It is also contraindicated in patients receiving anticoagulant therapy where bleeding risk is high.